2019 has not been kind to United Therapeutic's (UTHR) share price so far; the price has collapsed from a high of $125, to $78.54 at the time of writing.
Source: TradingView
The slump is mainly due to the expiry, or impending expiry of its exclusivity patents for key drug Adcirca, as well as the impending expiries, in 2026 and 2027 respectively, of Tyvaso and Orenitram, responsible for around 43% of the company's current revenues.
Background
United Therapeutics specialises in developing drugs that can help treat and eventually cure a condition known as Pulmonary